E-mail

E-mail a Wiley Online Library Link

Anne H. Blaes, Bruce A. Peterson, Nancy Bartlett, David L. Dunn and Vicki A. Morrison Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation Cancer 104

Version of Record online: 7 SEP 2005 | DOI: 10.1002/cncr.21391

Single-agent rituximab may offer a response and survival advantage in patients with posttransplant lymphoproliferative disorders. Further evaluation of rituximab in these disorders, potentially in combination with other therapies, is warranted.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH